Skip to main content

Table 1 Clinical characteristics of patients in the unweighted and weighed population

From: Necessity of external iliac lymph nodes and inguinal nodes radiation in rectal cancer with anal canal involvement

Characteristic

level

Overall

Unweighted population

Weighted population (IPTW)

Rb group, n (%)

P group, n (%)

p

Rb group, %

P group, %

p

n

 

399

290

109

    

Gender (%)

 

Female

170 (42.6)

116 (40.0)

54 (49.5)

0.109

42.5

47.1

0.441

 

Male

229 (57.4)

174 (60.0)

55 (50.5)

 

57.5

52.9

 

Age

 

 < 60

165(41.4)

194 (66.9)

71 (65.1)

0.832

68.3

62.8

0.328

 

 ≥ 60

134(33.6)

96 (33.1)

38 (34.9)

 

31.7

38.2

 

Concurrent chemotherapy regimen (%)

 

Single

232 (58.1)

177 (61.0)

55 (50.5)

0.001

59.5

57.4

0.840

 

Combined

143 (35.8)

103 (35.5)

40 (36.7)

 

35.0

35.6

 
 

None

24 (6.0)

10 (3.4)

14 (12.8)

 

5.4

7.0

 

Postoperative chemotherapy (%)

 

no

107 (26.9)

70 (24.2)

37 (33.9)

0.068

27.8

32.3

0.414

 

Yes

291 (73.1)

219 (75.8)

72 (66.1)

 

72.2

67.7

 

Radiotherapy strategies (%)

 

LCRT

36 (9.0)

26 (9.0)

10 (9.2)

 < 0.001

8.7

7.9

0.849

 

LCRT + SIB

344 (86.2)

258 (89.0)

86 (78.9)

 

86.5

85.8

 
 

SCRT

19 (4.8)

6 (2.1)

13 (11.9)

 

4.8

6.3

 

Number of dissected lymph nodes (%)

 

 < 12

195 (48.9)

151 (52.1)

44 (40.4)

0.006

49.6

46.0

0.245

 

 ≥ 12

195 (48.9)

136 (46.9)

59 (54.1)

 

49.1

49.5

 
 

none

9 (2.3)

3 (1.0)

6 (5.5)

 

1.3

4.5

 

cT (%)

 

cT1-3

158 (41.6)

122 (44.2)

36 (34.6)

0.115

44.3

34.6

0.107

 

cT4

222 (58.4)

154 (55.8)

68 (65.4)

 

55.7

65.4

 

cN (%)

 

cN-

43 (11.3)

30 (10.9)

13 (12.5)

0.790

10.4

11.1

0.844

 

cN + 

337 (88.7)

246 (89.1)

91 (87.5)

 

89.6

88.9

 

CEA, ng/nl (median [IQR])

3.3

[1.9,7.3]

3.5

[2.0, 7.6]

3.0

[1.7,6.1]

0.252

3.4

[1.9,7.6]

2.8

[1.7, 5.8]

0.191

CA199, U/ml (median [IQR])

12.6

[6.9,22.0]

12.5

[6.6,21.3]

12.8

[7.9,28.2]

0.112

12.7

[6.6, 21.7]

11.9

[7.9,25.8]

0.394

  1. LCRT Long course radiotherapy, SIB simultaneous integrated boost, SCRT short course radiotherapy, CEA carcinoembryonic antigen, CA199 carbohydrate antigen 19–9